Investigational Medication for COPD Lung Damage

Trial Objective

Our researchers are seeing if an investigational medication called Losartan helps people with chronic obstructive pulmonary disease (COPD) with emphysema, a disease of the lungs.

Investigational Medication for COPD Lung Damage

Often caused by cigarette smoking, COPD includes symptoms of emphysema and chronic bronchitis, including shortness of breath, long-term cough, fatigue, production of mucus, wheezing and fatigue. Although some COPD medications reduce symptoms and prevent flare-ups, few have been shown to reduce damage to the lungs in people with COPD. Losartan, a medicine used to treat high blood pressure, has been shown to slow lung damage caused by COPD in animals. 

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1233 or complete the form below.

Who Can Participate

People over 40 with mild-to-severe COPD are eligible to participate.


Estimated Time Commitment

7 visits, approximately 19 hours

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

National Heart, Lung, and Blood Institute (NHLBI) under the Pulmonary Trials Cooperative (PTC)

Age

40+


Gender

Any Gender


Request More Information

*
*
*
*